TILT Sets First Quarter 2024 Conference Call for May 15 at 5:00 p.m. ET
April 25, 2024 07:30 ET
|
TILT Holdings Inc.
PHOENIX, April 25, 2024 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT" or the “Company”) (Cboe: TILT) (OTCQB: TLLTF), a global provider of cannabis business solutions that include inhalation...
Streamline Health® Signs Second Enterprise Client
April 25, 2024 07:30 ET
|
Streamline Health Solutions, Inc.
700-Bed health system adds eValuator™, becomes second healthcare provider leveraging both eValuator and RevID to improve revenue integrity pre-bill Atlanta, GA, April 25, 2024 (GLOBE NEWSWIRE) --...
17 Education & Technology Group Inc. Files Its Annual Report on Form 20-F
April 25, 2024 07:30 ET
|
17 Education & Technology Group Inc.
17 Education & Technology Group Inc. Files Its Annual Report on Form 20-F
FTI Consulting Reports Record First Quarter 2024 Financial Results
April 25, 2024 07:30 ET
|
FTI Consulting, Inc.
First Quarter 2024 Revenues of $928.6 Million, Up 15% Compared to $806.7 Million in Prior Year QuarterFirst Quarter 2024 EPS of $2.23, Up 66% Compared to $1.34 in Prior Year Quarter WASHINGTON,...
Jushi Holdings Inc. to Report First Quarter 2024 Financial Results on May 9, 2024
April 25, 2024 07:30 ET
|
Jushi Holdings Inc.
BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that...
Kura Oncology to Report First Quarter 2024 Financial Results
April 25, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024 07:30 ET
|
XOMA Corporation
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...
Orezone Intersects 18.41 g/t Gold Over 8.00m and 22.17 g/t Gold Over 4.00m in Ongoing Exploration
April 25, 2024 07:30 ET
|
Orezone Gold Corporation
VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to provide drill results from its Bomboré...
Plato Gold Reports on 2023 Year-End Results
April 25, 2024 07:30 ET
|
Plato Gold Corp.
Toronto, ON, April 25, 2024 (GLOBE NEWSWIRE) -- Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company”) an exploration company with a portfolio of...
Global Scleral Lens Market Outlook 2023-2035: Market is Forecast to Garner Revenue of USD 0.87 billion by 2035, Up from USD 0.31 Billion in 2022
April 25, 2024 07:28 ET
|
Research and Markets
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Global Scleral Lens Market Outlook 2023-2035" report has been added to ResearchAndMarkets.com's offering.In an industry analysis of the global...